<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938793</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-15-11633</org_study_id>
    <nct_id>NCT02938793</nct_id>
  </id_info>
  <brief_title>Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors</brief_title>
  <official_title>A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prisma Health-Upstate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Prisma Health-Upstate</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator initiated single institution, open-label study to evaluate the&#xD;
      antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab&#xD;
      in subjects with select advanced rare solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated single institution, open-label study to evaluate the&#xD;
      antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab&#xD;
      in subjects with select advanced rare solid tumors. The dose-exploration phase, conducted&#xD;
      across a range of tumor types, has been completed. The dose-expansion phase is ongoing and&#xD;
      includes certain soft tissue sarcomas, neuroendocrine tumors and thymic carcinoma. Therefore,&#xD;
      subjects diagnosed with any of those rare tumors are excluded from this trial. Given the&#xD;
      safety and tolerability data in the previous and ongoing studies (Study D4190C00010 and&#xD;
      D4190C00006), the selected dose for evaluation in all subjects enrolled in this trial is as&#xD;
      follows:&#xD;
&#xD;
      Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and&#xD;
      Tremelimumab 300 mg intravenously as a single dose on cycle 1 day 1 only. Weight-based dosing&#xD;
      should be utilized for patients &lt;30 kg: durvalumab 20 mg/kg and tremelimumab 1 mg/kg.&#xD;
      Tremelimumab will be administered first and the infusion duration will be approximately 1&#xD;
      hour. The durvalumab infusion will start approximately 1 hour after the end of the&#xD;
      tremelimumab infusion and the infusion will be administered over approximately 1 hour.&#xD;
&#xD;
      The project Surveillance of Rare Cancers in Europe (RARECARE) collected data on cancers from&#xD;
      89 population-based cancer registries in 21 European countries, making it possible to study&#xD;
      the epidemiology of these cancers as a whole in a large and heterogeneous population. Working&#xD;
      from this database and the literature, a RARECARE working group produced a new list of&#xD;
      cancers and developed a new definition of rare cancers (incidence &lt; 6/100,000/year). This&#xD;
      definition and working list are adopted for this rare tumor immunotherapy study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor Activity</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the antitumor activity of durvalumab in combination with tremelimumab based on immune-related Response Evaluation Criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent and Non Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>24 months</time_frame>
    <description>To assess the safety and tolerability of durvalumab in combination with tremelimumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of programmed cell death protein 1 (PD-1)</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the pharmacodynamic activity of durvalumab in combination with tremelimumab in the tumor microenvironment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <condition>Rare Disease</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>CP-675,206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of a rare advanced solid malignancy meeting EORTC criteria.&#xD;
&#xD;
          -  Subjects must have failed or been ineligible to receive standard treatment options if&#xD;
             available.&#xD;
&#xD;
          -  Subjects must be amenable to biopsy of a tumor site or have recent (&lt; 2 years)&#xD;
             archival material available.&#xD;
&#xD;
          -  ECOG performance status of 0 to 2.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Adequate normal organ and marrow function including: hemoglobin &gt; 9.0 g/dl; ANC &gt; 1500&#xD;
             per mm3; platelet count &gt; 100,000 per mm3; bilirubin &lt; 1.5 x ULN; ALT/AST &lt; 2.5 x ULN&#xD;
             unless liver metastases present in which case must be &lt; 5 x ULN; creatinine clearance&#xD;
             &gt; 40 ml/min by Cockcroft-Gault or 24 hour urine collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with durvalumab or tremelimumab.&#xD;
&#xD;
          -  Prior treatment with any checkpoint inhibitor (including anti-CTLA-4, anti-PD-1 and&#xD;
             anti-PD-L1).&#xD;
&#xD;
          -  Rare malignancies under investigation in other studies including thymic carcinoma,&#xD;
             certain sarcomas, and neuroendocrine tumors.&#xD;
&#xD;
          -  Untreated central nervous system metastatic disease.&#xD;
&#xD;
          -  Active or documented autoimmune disease within previous 2 years.&#xD;
&#xD;
          -  Uncontrolled psoriasis.&#xD;
&#xD;
          -  Prior chemotherapy within 28 days of the first dose of durvalumab or tremelimumab.&#xD;
&#xD;
          -  Steroid exposure within 28 days of the first dose of durvalumab or tremelimumab with&#xD;
             the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids&#xD;
             at physiological doses, which are not to exceed 10 mg/day of prednisone, or an&#xD;
             equivalent corticosteroid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Edenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prisma Health-Upstate</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie C Martin, DNP</last_name>
    <phone>864-455-3600</phone>
    <phone_ext>3667</phone_ext>
    <email>julie.martin@prismahealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Kueber, RN, BSN</last_name>
    <phone>864-455-3600</phone>
    <phone_ext>3774</phone_ext>
    <email>jan.kueber@prismahealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Davidson, RN, BSN</last_name>
      <phone>864-455-3600</phone>
      <phone_ext>3737</phone_ext>
      <email>fiona.davidson@prismahealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa M Johnson, RN, BSN</last_name>
      <phone>8644553600</phone>
      <phone_ext>3735</phone_ext>
      <email>lisa.johnson@prismahealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>W. Jeff Edenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ki Y Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer, malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>aggregate data only</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

